Edition:
United Kingdom

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.03USD
19 Oct 2018
Change (% chg)

$-0.02 (-1.90%)
Prev Close
$1.05
Open
$1.05
Day's High
$1.06
Day's Low
$1.02
Volume
71,429
Avg. Vol
66,129
52-wk High
$2.44
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Scynexis Provides Corporate And SCY-078 Pipeline Update
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Scynexis Inc ::SCYNEXIS PROVIDES CORPORATE AND SCY-078 PIPELINE UPDATE.SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​.SCYNEXIS INC - ‍PLANS TO INITIATE A PHASE 2B STUDY OF SCY-078 IN INVASIVE CANDIDIASIS WITH LIPOSOMAL IV FORMULATION IN Q4 OF 2018​.SCYNEXIS - ‍ANTICIPATES DOSE REGIMEN SELECTED FROM DOVE STUDY TO BE SUBSEQUENTLY EVALUATED IN PHASE 3 STUDIES FOLLOWING END-OF-PHASE 2 MEETING WITH FDA​.  Full Article

Scynexis reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

SCYNEXIS says achieves new development milestones for SCY-078
Tuesday, 13 Dec 2016 

SCYNEXIS Inc : Pending discussions with FDA, plan to test in upcoming clinical trials of SCY-078 . Scynexis achieves new development milestones reinforcing versatility of SCY-078 in treating serious fungal infections .SCY-078 toxicology program was expanded to include three-month oral dose studies in two species.  Full Article

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE